The necessity for clinical reasoning in the era of evidence-based medicine.
暂无分享,去创建一个
C. Furberg | K. Lachapelle | A. Sniderman | Curt D Furberg | Allan D Sniderman | Kevin J LaChapelle | Nikodem A Rachon | N. Rachon
[1] P. Rothwell,et al. External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.
[2] P. Kolh,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.
[3] C. Furberg,et al. Why guideline-making requires reform. , 2009, JAMA.
[4] H. Krumholz,et al. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. , 2012, Circulation. Cardiovascular quality and outcomes.
[5] John P A Ioannidis,et al. Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. , 2011, Journal of clinical epidemiology.
[6] C. Furberg,et al. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. , 2012, Journal of clinical lipidology.
[7] R. Hayward,et al. Beyond the Randomized Clinical Trial the Role of Effectiveness Studies in Evaluating Cardiovascular Therapies the Achilles' Heel of Rcts Key Issues in Outcomes Research , 2022 .
[8] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.
[9] R. Hegele,et al. Narrative Review: Statin-Related Myopathy , 2009, Annals of Internal Medicine.
[10] A. Garg,et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases , 2013, BMJ.
[11] J. Kassirer,et al. Learning Clinical Reasoning , 1991 .
[12] S. Rogers,et al. Prevention of infective endocarditis' , 1988, British Dental Journal.
[13] Ian Graham,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.
[14] Richard L Kravitz,et al. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. , 2004, The Milbank quarterly.
[15] Paul Tibbetts,et al. Meaning and Action: A Critical History of Pragmatism , 1972 .
[16] J. Ioannidis. Contradicted and Initially Stronger Effects in Highly Cited Clinical Research , 2005 .
[17] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[18] D. Sackett,et al. Evidence based medicine: what it is and what it isn't , 1996, BMJ.
[19] F. Gueyffier,et al. Pharmacotherapy for mild hypertension (Review) , 2012 .
[20] L. Cohen. An Introduction To The Philosophy Of Induction And Probability , 1989 .
[21] C. Warlow,et al. Prediction of benefit from carotid endar terectomy in individual patients: a risk-modelling study , 1999, The Lancet.
[22] M A Gerber,et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. , 1990, JAMA.
[23] P. Toth. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .
[24] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[25] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[26] Pat Croskerry,et al. From mindless to mindful practice--cognitive bias and clinical decision making. , 2013, The New England journal of medicine.
[27] The Philosophy of Evidence-Based Medicine , 2013 .
[28] A. B. Hill. Reflections on controlled trial. , 1966, Annals of the rheumatic diseases.
[29] P. Ridker,et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. , 2012, Clinical chemistry.
[30] John P A Ioannidis,et al. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients , 2013, BMJ : British Medical Journal.
[31] P. Sipponen,et al. What fraction of hospital ulcer patients is eligible for prospective drug trials? , 1991, Scandinavian journal of gastroenterology. Supplement.
[32] Jane M Blazeby,et al. Challenges in evaluating surgical innovation , 2009, The Lancet.
[33] R. Califf,et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. , 2009, JAMA.
[34] W. Rogers,et al. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.
[35] Robert Dufour,et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. , 2013, The Canadian journal of cardiology.
[36] Hill Ab. Reflections on controlled trial. , 1966 .
[37] M. Weir,et al. The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .
[38] Larry M Baddour,et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Card , 2007, Circulation.
[39] J. Howick,et al. Philosophy of Evidence-Based Medicine , 2011 .
[40] F. Gueyffier,et al. Pharmacotherapy for mild hypertension. , 2012, The Cochrane database of systematic reviews.